Caladrius Biosciences (Formerly NeoStem)

Caladrius Biosciences Summary Financials People Technology Signals & News About Caladrius Biosciences is a clinical-stage biopharmaceutical company. Basking Ridge, New Jersey, United States 101-250 Post-IPO Equity Public www.caladrius.com/ 9,112 Highlights Stock Symbol NASDAQ:CLBS Number of Acquisitions 4 Total Funding Amount $154.9M Number of Current Team Members 2 Number of Investors 3 Recent News & Activity News • Mar 28, 2021 techinvestornews.com — Caladrius Biosciences, Inc. (NASDAQ:CLBS) Sees Significant Increase in Short Interest Funding Round • Feb 12, 2021 Caladrius Biosciences raised $65,000,000 / Post Ipo Equity Discover more funding rounds News • Feb 11, 2021 techinvestornews.com — Caladrius Biosciences (NASDAQ:CLBS) Trading 16.7% Higher VIEW ALL Details Industries Biotechnology Pharmaceutical Therapeutics Diversity Spotlight (US Only) Women Founded Headquarters Regions Greater New York Area, East Coast, Northeastern US Founded Date 2006 Founders Catherine Vaczy Operating Status Active Last Funding Type Post-IPO Equity Also Known As NeoStem, Inc Legal Name Caladrius Biosciences, Inc. Stock Symbol NASDAQ:CLBS Company Type For Profit Phone Number (908)842-0100 Caladrius Biosciences is a clinical-stage biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. The company's current product candidates include three developmental treatments for cardiovascular diseases based on CD34+ cell therapy platform: CLBS12, recipient of a SAKIGAKEdesignation in Japan and advanced therapy medicinal product classification (ATMP) in Europe, eligible for early conditional approval for the treatment of critical limb ischemia in Japan based on an ongoing clinical trial; CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial in the U.S.A. and CLBS14, a Phase 3 clinical program in no option refractory disabling angina and recipient of a RMAT designation in the U.S.A.